9. bibliography -...
TRANSCRIPT
229
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
9. BIBLIOGRAPHY
Acikgoz, M., Kas, H.S., Hascelik, Z., Milli, U., Hincal, A.A., 1995. Chitosan
microspheres of diclofenac sodium, II: In vitro and in vivo evaluation. Pharmazie.
50: 275–277.
Agnihotri, S.A., Aminabhavi, T.M., 2004. Controlled release of clozapine through
chitosan microparticles prepared by a novel method. J. Control. Release. 96:
245–259.
Ainsworth, M.A., Hogan, D.L., Koss, M.A., Isenberg, J.I., 1993. Cigarette smoking
inhibits acid stimulated duodenal mucosal bicarbonate secretion. Ann. Intern.
Med. 119: 882-886.
Akiyama, Y., Nagahara, N., 1999. Novel formulation approaches to oral
mucoadhesive drug delivery systems. In: Mathiowitz, E., Chickering, D.E. III,
Lehr, C.M. (Eds.), Bioadhesive Drug Delivery Systems—Fundamentals, Novel
Approaches and Development. Marcel Dekker, New York, pp. 477–505.
Akiyama, Y., Nagahara, N., Kashihara, T., Hirai, S., Toguchi, H., 1995. In vitro and
in vivo evaluation of mucoadhesive microspheres prepared for the gastrointestinal
tract usingpolyglycerol esters of fatty acids and a poly (acrylic acid) derivative.
Pharm. Res. 12: 397–405.
Akiyama, Y., Nagahara, N., Nara, E., Kitano, M., Iwasa, S., Yamamoto, I., Azuma, J.,
Ogawa, Y., 1998. Evaluation of oral mucoadhesive microspheres in man on the
basis of the pharmacokinetics of furosemide and riboflavin, compounds with
limited gastrointestinal absorption sites. J. Pharm. Pharmacol. 50: 159–166.
Amdrup, E., Brandsborg, M., Brandsborg, O., Lovgreen, N.A., 1979. Interrelationship
between serum gastrin concentration, gastric acid secretion, and gastric emptying
rate in recurrent peptic ulcer. World J. Surg. 3:235-240.
Amini, H., Ahmadiani, A., 2005. Sensitive determination of clarithromycin in human
plasma by high performance liquid chromatography with spectrophotometric
detection. J.Chromatogr. B. 817: 193–197.
An, Y.H., Friedman, R.J., 2000. In: An, Y.H., Friedman, R.J., (Eds), Handbook of
Bacterial Adhesion. Principles, Methods, and Applications, Humana press Inc,
Totowa, pp. 91-102.
230
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Anderson, D.M., Brydon, W.G., Eastwood, M.A., Sedgwick, D.M., 1991. Dietary
effects of sodium alginate in humans. Food. Addit. Contam. 8: 237–248.
Andersson, T., 1996. Pharmacokinetics, metaholism and interactions of acid pump
inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin.
Pharrnacokiner. 31: 9-28.
Antos, D., Enders, G., Rieder, G., Stolte, M., Bayerdorffer, E., Hatz, R.A., 2001.
Inducible nitric oxide synthase expression before and after eradication of
Helicobactor pylori in different forms of gastritis. FEMS Immunol. Med.
Microbiol. 30: 127–131.
Arai, K., Kinumaki, T., Fujita, T., 1968. Toxicity of chitosan. Bull.Tokai. Reg. Fish.
Res. Lab. 43: 89–94.
Arnold, R.S., Shi, J., Murad, E., Whalen, A.M., Sun, C.Q., Polavarapu, R., et al.,
2001. Hydrogen peroxide mediates the cell growth and transformation caused by
the mitogenic oxidase. Nox1. Proc. Natl. Acad. Sci. U. S. A. 98: 5550–5555.
Arora, S., Ali, J., Ahuja, A., Khar, R.K., Baboota, S., 2005. Floating drug delivery
systems: a review. AAPS Pharm. Sci. Technol. 6: 47.
Atherton, J.C., 1997.The clinical relevance of strain types of Helicobactor pylori. Gut.
40: 701–703.
Atherton, J.C., Cao, P., Peek Jr, R.M., Tummuru, M.K., Blaser, M.J., Cover, T.L.,
1995. Mosaicism in vacuolating cytotoxin alleles of Helicobactor pylori.
Association of specific vacA types with cytotoxin production and peptic
ulceration. J. Biol. Chem. 270: 17771–17777.
Attia, M.A., ElGibaly, I., Slialtout, S.E., 2004. Transbuccal permeation, anti-
inflammatory and clinical efficacy of piroxicam formulated in different gels. Int.
J. Pharm. 276: 11–28.
Atyabi, F., Sharma, H.L., Mohammad, H.A.H., Fell, J.T., 1996a. Controlled drug
release from coated floating ion exchange resin beads. J. Control. Release. 42:
25–28.
Atyabi, F., Sharma, H.L., Mohammad, H.A.H., Fell, J.T., 1996b. In vivo evaluation of
a novel gastric retentive formulation based on ion exchange resins. J. Control.
Release. 42: 105–113.
231
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Augusto, A.C., Miguel, F., Mendonça, S., Pedrazzoli Jr, J., Gurgueira S.A., 2007.
Oxidative stress expression status associated to Helicobactor pylori virulence in
gastric diseases. Clin. Biochem. 40: 615–622
Azarmi, S., Valizadeh, H., Barzegar, J.M., Loebenberg, R., 2003. In situ crosslinking
of polyanionic polymers to sustain the drug-release of acetazolamide tablets.
Pharm. Ind. 63: 877–881.
Badve, S.S., Sher, P., Korde, A., Pawar, A.P., 2007. Development of hollow/porous
calcium pectinate beads for floating-pulsatile drug delivery, Eur. J. Pharm.
Biopharm. 65: 85–93.
Badwan, A.A., 2002. Pantoprazole sodium. In: Florey, K.,Brittain, H.G. (Eds.),
Analytical Profiles of Drug Substances andExcipients, vol. 29. Academic Press,
Elsevier Science, USA, pp.213–259.
Bagchi, D., Bhattacharya, G., Stohs, S.J., 1996. Production of reactive oxygen species
by gastric cells in association with Helicobactor pylori. Free Radic. Res. 24: 439–
450.
Balasubramaniam, J., Pandit, J.K., 2003. Ion activated in situ gelling systems for
sustained release ophthalmic delivery of ciprofloxacin hydrochloride. Drug.
Delivery. 10: 185–191.
Bardhan, P.K., 1997. Epidemiological features of Helicobactor pylori infection in
developing countries. Clin. Infect. Dis. 25: 973–978.
Bardonnet, P.L., Faivre, V., Pugh, W.J., Piffaretti, J.C., Falson, F., 2006.
Gastroretentive dosage forms: overview and special case of Helicobactor pylori.
J. Control. Release. 111: 1–18.
Bassily, S., Frenck, R.W., Mohareb, E.W., Wierzba, T., Savarino, S., et al., 1999.
Seroprevalenceof Helicobactor pylori among Egyptian newborns and their
mothers: a preliminary report. Am. J. Trop. Med. Hyg. 61: 37–40.
Bauditz, J., Ortner, M., Bierbaum, M., Niedobitek, G., Lochs, H., Schreiber, S., 1999.
Production of IL-12 in gastritis relates to infection with Helicobactor pylori. Clin.
Exp. Immunol.117: 316– 323.
Baumgartner, S., Kristl, J., Vrecer, F., Vodopivec, P., Zorko, B., 2000. Optimization
of floating matrix tablets and evaluation of their gastric residence time. Int. J.
Pharm. 195: 125–135.
232
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Bayomi, M.A., Al-Suwayeh, S.A., El-Helw, A.M., Mesnad, A.F., 1998. Preparation
of casein-chitosan microspheres containing diltiazem hydrochloride by an aqueous
coacervation technique. Pharma. Acta. Helv. 73: 187–192.
Bechgaard, H., Ladefoged, K., 1978a. Distribution of pellets in the gastrointestinal
tract. The influence on transit time exerted by the density or diameter of pellets. J.
Pharm. Pharmacol. 30: 690–692.
Bechgaard, H., Nielson, G.H., 1978b. Controlled release multiple units and single unit
doses. Drug Dev. Ind. Pharm. 4: 53–67.
Beckert, T.E., Lehmann, K., Schmidt, P.C., Compression of enteric coated pellets to
disintegrating tablets. Int. J. Pharm. 143: 13– 23.
Beil, W., Kilian, P., 2007. EPs-7630, an extract from Pelargonium sidoides roots
inhibits adherence of Helicobactor pylori to gastric epithelial cells.
Phytomedicine. 14: 5–8.
Blair, A.J., Feldman, M., Barnett, C., Walsh, J.H., Richardson, C.T., 1987. Detailed
comparison of basal and food-stimulated gastric acid secretion rates and serum
gastrin concentrations in duodenal ulcer patients and normal subjects. J. Clin.
Invest. 79: 582-587.
Blaser, M.J., 1992. Hypotheses on the pathogenesis and natural history of
Helicobactor pylori induced inflammation. Gastroenterolog. 102: 720-727.
Blaser, M.J., 1997. Not all Helicobactor pylori strains are created equal: should all be
eliminated? Lancet. 349: 1020-1022.
Blaser, M.J., Berg, D.E., 2001. Helicobactor pylori genetic diversity and risk of
human disease. J. Clin. Invest. 107: 767-773.
Bliesath, H., Huber, R., Hartmann, M., Luhmann, R., Wurst, W., 1994., Dose linearity
of the pharmacokinetics of the new H+/K+-ATPase inhibitor Pantoprazole after
single intravenous administration. Znt. J. Clin. Pharmacol. Ther. 32: 44-50.
Bliesath, H., Huber, R., Steinijans, V.W., Koch, H.J., Kunz, K., Wurst, W., 1996.
Pantoprazole does not interact with nifedipine in man under steadystate
conditions. Int. J. Clin. Pharmacol. Ther. 34: 51–5.
Bodmeier, R., Chen, H., Paeratakul, O., 1989. A novel approach to the oral delivery
of micro or nanoparticles. Pharm. Res. 6: 413–417.
233
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Bodmeier, R., Wang, J., 1993. Microencapsulation of drugs with aqueous colloidal
polymer dispersions. J. Pharm. Sci. 82: 191–194.
Borlace, G.N., Butler, R.N., Brooks, D.A., 2008. Monocyte and macrophage killing of
Helicobactor pylori: relationship to bacterial virulence factors. Helicobacter. 13:
380–387.
Braccini, I., Perez, S., 2001. Molecular basis of Ca2+-induced gelation in alginates
and pectins: The egg box model revisited. Biomacromolecules, 2: 1089–1096.
Bugaj, J., Gorecki, M., 1995. Kinetics of dynamic viscosity changes of aqueous
sodium carboxymethylcellulose and sodium alginate solutions. Pharmazie. 50:
750–752.
Bugaj, J., Gorecki, M., 1996. Rheometrical estimation of physical properties of
sodium alginate and sodium carboxymethylcellulose aqueous solutions. Acta. Pol.
Pharm. Drug. Res. 53: 141–146
Bulgarelli, E., Forni, F., Bernabei, M.T., 2000. Effect of matrix composition and
process conditions on casein gelatin beads floating properties. Int. J. Pharm. 198:
157–165.
Burger, G.T., Miller, L.C., 1989. Principles and Methods of Toxicology, 2nd ed.,
ed. A. W. Hayes. New York: Raven Press, pp. 35.
Buri, P., 1985. Voie oral. In: Buri, P., Puisieux, F., Doelker, E., Benoit, J.P. (Eds.),
Formes Pharmaceutiques Nouvelles, Techniques et Documentation. Lavoisier,
Paris, pp. 175–228.
Butler, J., Ness, R., Speroff, T., 2001. Improving care for elderly patients with peptic
ulcer disease: should the focus be on drugs or bugs? J.A.M.A. 286: 2023-2024.
Byrne, R.S., Deasy, P.B., 2002. Use of commercial porous ceramic particles for
sustained drug delivery. Int. J. Pharm. 246: 61–73.
Calvet, X., Garcia, N., Lopez, T., Gisbert, J.P., Gene, E., Roque, M. A., 2000. A
meta-analysis of short versus long therapy with a proton pump inhibitor,
clarithromycin, and either metronidazole or amoxicillin for treating Helicobactor
pylori infection. Aliment. Pharmacol. Ther. 4: 603-609.
Cargill, R., Caldwell, L., Engle, K., Fix, J., Porter, P., Gardner, C., 1988. Controlled
gastric emptying. I. Effects of physical properties on gastric residence times of
non-disintegrating geometric shapes in beagle dogs. Pharm. Res. 5: 533–536.
234
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Cargill, R., Engle, K., Gardner, C., Porter, P., Sparer, R., Fix, J., 1989. Controlled
gastric emptying II. In-vitro erosion and gastric residence times of an erodible
device in beagle dogs. Pharm. Res. 6: 506–509.
Catrenich, C.E., Makin, K.M., 1991. Characterization of the morphologic conversion
of Helicobactor pylori from bacillary to coccoid forms. Scand. J. Gastroenterol.
26: 58-64.
Chang, R.K., Peng, RE., Shukla, Y., 2006, Polymethacrylates, In Rowe,R.C., Paul, J.,
Sheskey,P.J., Owen, S,C., (eds)., Hand book of Pharmaceutical excipients,
Pharmaceutical Press and the American Pharmacists Association,Wahington
U.S.A., pp.345-365
Chavanpatil, M.D., Jain, P., Chaudhari, S., Shear, R., Vavia, P.R., 2006. Novel
sustained release, swellable and bioadhesive gastroretentive drug delivery system
for ofloxacin. Int. J. Pharm. 316: 86–92.
Chen, J., Blevins, W.E., Park, H., Park, K., 2000. Gastric retention properties of
superporous hydrogel composites. J. Control. Release. 64: 39–51.
Chen, J., Park, H., Park, K., 1999. Synthesis of superporous hydrogels: Hydrogels
with fast swelling and superabsorbent properties. J. Biomed. Mater. Res. 44: 53–
62.
Chien, Y.W., 1992. Oral drug delivery and delivery systems. In: Chien, Y.W. (Ed.),
Novel Drug Delivery Systems. Marcel Dekker, New York, pp. 139–196.
Chitnis, V.S., Malshe, V.S., Lalla, J.K., 1991. Bioadhesive polymers synthesis,
evaluation and application in controlled release tablets. Drug Dev. Ind. Pharm. 17:
879–892.
Chng, H.S., Park, H., Kelly, P., Robinson, R., 1985. Bioadhesive polymers as
platforms for oral controlled drug delivery II: synthesis and evaluation of some
swelling water-insoluble bioadhesive polymers. J. Pharm. Sci. 74: 399–405.
Choi, B.Y., Park, H.J., Hwang, S.J., Park, J.B., 2002. Preparation of alginate beads for
floating drug delivery system: effects of CO2 gas-forming agents. Int. J. Pharm.
239: 81–91.
Chourasia, M.K., Jain, S.K., 2003. Pharmaceutical approaches to colon targeted drug
delivery systems. J. Pharm. Pharm. Sci. 6: 33–66.
235
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Chu, S.Y., Sennello, L.T., Sonders, R.C., 1991. Simultaneous determination of
clarithromycin and 14-hydroxy-clarithromycin in plasma and urine using HPLC
with electronical detection. J. Chromatogr. Biomed. Appl. 571: 199-208.
Chueh, H.R., Zia, H., Rhodes, C.T., 1995. Optimization of sotalol floating and
bioadhesive extended release tablet formulations. Drug. Dev. Ind. Pharm. 21:
1725–1747.
Clemens, J., Albert, M.J., Rao, M., Huda, S.F., Qadri, F.P., Van Loon, B., et al., 1996.
Sociodemographic, hygienic and nutritional correlates of Helicobactor pylori
infection of young Bangladeshi children, Pediatr. Infect. Dis. J. 15: 1113–1118.
Clyne, M., Labigne, A., Drumm, B., 1995. Helicobactor pylori require an acidic
environment to survive in the presence of urea. Infect. Immun. 63: 1669–1673.
Coates, D., Richardson, G., 1974. A note on the production of sterile solutions of
sodium alginate. Can. J. Pharm. Sci. 9: 60–61.
Cohen, H., 2000. Peptic ulcer and Helicobactor pylori. Gastroenterol. Clin. North
Am. 29: 775-789.
Cohen, S., Lobel, E., Trevgoda, A., Peled, Y., 1997. A novel in situ forming
ophthalmic drug delivery system from alginates undergoing gelation in the eye. J.
Control. Release. 44: 201–208.
Cooreman, M.P., Krausgrill, P., Hengels, K.J., 1993. Local gastric and serum
amoxycillin concentrations after different oral application forms. Antimicrob.
Agents Chemother. 37: 1506–1509.
Cox, A.M., 1952. Stomach size and its relation to chronic peptic ulcer. Arch. Pathol.
54: 407-422.
Crabtree, J.E., Figura, N., Taylor, J.D., Bugnoli, M., Armellini, D., Tompkins, D.S.,
1992. Expression of 120 kilodalton protein and cytotoxicity in Helicobactor
pylori. J. Clin. Pathol. 45: 733–736.
Cryer, B., Feldman, M., 1994. Peptic ulcer disease in the elderly. Semin. Gastrointest.
Dis. 5:166-178
Cryer, B., Lee, E., Feldman, M., 1992. Factors influencing gastroduodenal mucosal
prostaglandin concentrations: roles of smoking and aging. Ann. Intern. Med. 116:
636-640.
236
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Cuna, M., Alonso, M.J., Torres, D., 2001. Preparation and in vivo evaluation of
mucoadhesive microparticles containing amoxicillin–resin complexes for drug
delivery to the gastric mucosa. Eur. J. Pharm. Biopharm. 51: 199–205.
Danesh, J., Appleby, P., Peto, R., 1998. How often does surgery for peptic ulceration
eradicate Helicobactor pylori? Systematic review of 36 studies. B.M.J. 316: 746-
7.
Daumesnil, R., 1994. Marketing considerations for multi-particulate drug delivery
systems. In: Ghebre-Sellassie, I. (Ed.), Multiparticulate Oral Drug Delivery.
Marcel Dekker Inc, New York, pp. 457–474.
Davis, S.S., Khosla, R., Wilson, C.G., Washington, N., 1987. Gastrointestinal transit
of controlled-release pellet formulation of tiaprofenic acid and the effect of food.
Int. J. Pharm. 35: 253–258.
Davis, S.S., Stockwell, A., Taylor, M., Hardy, J., Whalley, D., et al., 1986. The effect
of density on the gastric emptying of single multiple unit dosage forms. Pharm.
Res. 3: 208–213.
Dekkers, C.P.M., Beker, J.A., Thjodleifsson. B., Gabryelewicz, A., Bell, N.E.,
Humphries, T.J., 1999. Comparison of rabeprazole 20 mg versus omeprazole 20
mg in the treatment of active duodenal ulcer: a European multicentre study.
Aliment. Pharmacol. Ther. 13: 179-86.
Desai, S., Bolton, S., 1993. A floating controlled-release drug delivery system: in
vitro in vivo evaluation. Pharm. Res. 10: 1321–1325.
Deshpande, A.A., Rhodes, C.T., Shah, N.H., Malick, A.W., 1996. Controlledrelease
drug delivery systems for prolonged gastric residence: an overview. Drug. Dev.
Ind. Pharm. 22: 531–539.
Deshpande, A.A., Shah, N.H., Rhodes, C.T., Malick, W., 1997. Development of a
novel controlled release system for gastric retention. Pharm. Res. 14: 815-/819.
Dettmar, P.W, Lloyd-Jones, J.G., 1994. Method of treatment of Heliobacter pylori
infections with triclosan, US patent 5286492.
Dodane, V., Vilivalam, V.D., 1998. Pharmaceutical applications of chitosan. P.S.T.T.
1: 246–253.
237
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Dore, M.P., Leandro, G., Realdi, G., Sepulveda, A.R., Graham, D.Y., 2000. Effect of
pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome
of Helicobactor pylori therapy. Dig. Dis. Sci. 45: 68-76.
Duggirala, S., DeLuca, P.P., 1996. Buffer uptake and mass loss characteristics of
freeze-dried cellulosic and alginate devices. P.D.A. J. Pharm. Sci. Technol. 50:
297–305.
Duggirala, S., DeLuca, P.P., 1996. Rheological characterization of cellulosic and
alginate polymers. P.D.A. J.Pharm. Sci. Technol. 50: 290–296.
Dunn, B.E., Cohen, H., Blaser, M.J., 1997. Helicobactor pylori. Clin. Microbiol.Rev.
10: 720–741.
Eaton, K.A., Brooks, C.L., Morgan, D.R., Krakowka, S., 1991. Essential role of
urease in pathogenesis of gastritis induced by Helicobactor pylori in gnotobiotic
piglets. Infect. Immun. 59: 2470–2475.
Efentakis, M., Koutlis, A., Vlachou, M., 2000. Development and evaluation of oral
multiple unit and single unit hydrophilic controlled release systems. AAPS
Pharm.Sci.Tech. 1: 34.
Egan, B.J, Katicic, M., O’Connor, H.J., O’Morain, C.A., 2007. Treatment of
Helicobactor pylori. Helicobacter, 12: 31–37.
El-Gibaly, I., 2002. Development and in vitro evaluation of novel floating hitosan
microcapsules for oral use: comparison with non-floating chitosan microspheres.
Int. J. Pharm. 249: 7-/21.
El-Kamel, A.H., Sokar, M.S., Al Gamal, S.S., Naggar, V.F., 2001. Preparation and
evaluation of ketoprofen floating oral delivery system. Int. J. Pharm. 220: 13–21.
El-Serag, H.B., Sonnenberg, A., 1998. Opposing time trends of peptic ulcer and reflux
disease. Gut. 43: 327-33.
Endo, H., Yoshida, H., Ohmi, N., Ohta, K., Higuchi, S., 2001. Localization of 14
C
amoxicillin in rat gastric tissue when administered with lansoprazole and
clarithromycin. J. Antimicrob. Chemother. 48: 923–926.
Endo, H., Yoshida, H., Ohmi, N., Ohta, K., Higuchi, S., Suga, T., 2002. Localization
of 14
C clarithromycin in rat gastric tissue when administered with lansoprazole
and amoxicillin. J. Antimicrob. Chemother. 50: 285–288.
238
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Erah, P., Goddard, A., Barrett, D., Shaw, P.N., Spiller, R.C., 1997. The stability of
amoxicillin,clarithromycin and metronidazole in gastric juice: Relevance to the
treatment of Helicobactor pylori infection. J. Antimicrob. Chemother. 39:5–12.
Errington, N., Harding, S.E., Varum, K.M., Illum, L., 1993. Hydrodynamic
characterization of chitosans varying in degree of acetylation. Int. J. Biol.
Macromol. 15: 113–117.
Eslick, G.D., 2004. Non-gonococcal urethritis, Helicobactor pylori infection and
fellatio: a new menageatrois? Microbiology. 150:520–522.
Falk, P., Roth, K.A., Boren, T., Westblom, T.U., Gordon, J.I., 1993. An in vitro
adherence assay reveals that Helicobactor pylori exhibits cell lineage-specific
tropism in the human gastric epithelium. Proc. Natl. Acad. Sci. U. S. A. 90: 2035–
2039.
Fang, Y., Al-Assaf, S., Phillips, G.O., Nishinari, K., Funami, T., Williams, P.A.,
2008. Binding behavior of calcium to polyuronates: Comparison of pectin with
alginate. Carbohydrate Polymers. 72, 334–341
FAO/WHO, 1992. Evaluation of certain food additives and naturally occurring
toxicants. Thirty-ninth report of the joint FAO/WHO expert committee on food
additives. World Health Organ. Tech. Rep. Ser. No. 828.
Fedwick, J.P., Lapointe, T.K., Meddings, J.B., Sherman, P.M., Buret, A.G., 2005.
Helicobactor pylori activates myosin light-chain kinase to disrupt claudin-4 and
claudin-5 and increase epithelial permeability. Infect. Immun. 73: 7844–7852.
Feldman, M., 2002. Gastric secretion. In: Feldman M, editor. Sleisenger and
Fordtran’s Gastrointestinal and Liver Disease. 7th ed. Elsevier, Philadelphia, PA.,
pp. 715-731.
Feldman, M., Richardson, C.T., 1986. Total 24-hour gastric acid secretion in patients
with duodenal ulcer: comparison with normal subjects and effects of cimetidine
and parietal cell vagotomy. Gastroenterology. 90: 540-544.
Feliciano, D.V., Ojukwu, J.C., Rozycki, Ballard, R.B., Ingram, W.L., et al., 1999. The
epidemic of cocaine-related juxta pyloric perforations: with a comment on the
importance of testing for Helicobactor pylori. Ann. Surg. 229: 801-804.
Fell, J.T., 1999. Delivery systems for targeting to specific sites in the gastrointestinal
tract. J. Pharm. Pharmacol. 51: 41.
239
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Fennerty, M.B., 1994. Helicobactor pylori. Arch. Int. Med. 154: 721-727.
Ferrero, J. L., Bopp, B A., Marsh, K C., Quigley, S C., Johnson, M. J., et al., 1990.
Metabolism and disposition of clarithromycin in man. Drug Metab. Dispos. 18:
441-44.
Fisher, R.S., Cohen, S., 1973. Pyloric-sphincter dysfunction in patients with gastric
ulcer. N. Engl. J. Med. 288: 273-276.
Fitton, A., Wiseman, L., 1996. Pantoprazole. A review of its pharmacological
properties and therapeutic use in acid-related disorders. Drags. 51:460-482.
Fix, J.A., Cargill, R., Engle, K., 1993. Controlled gastric emptying, Part 3. Gastric
residence time of a nondisintregrating geometric shape in human volunteers.
Pharm. Res. 10: 1087–1089.
Fontana, G., Licciardi, M., Mansueto, S., Schillaci, D., Giammona, G., 2001.
Amoxicillin loaded polyethylcyanoacrylate nanoparticles: influence of PEG
coating on the particle size, drug release rate and phagocytic uptake. Biomaterials.
22: 2857–2865.
Fraschini, F., Scaglione, F., Demartini, G., 1993. Clarithromycin, clinical
pharmacokinetics. Clin. Pharmacokinet.25:189-204.
Fraschini, F.,Scaglione, F., Pintucci, G., Maccarinelli, G., Dugnani, S., Demartini, G.,
1991. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil
and lung in humans. J. Antimicrob. Chemother. 27: 61-65.
Fraser, A.G, Scragg, R., Metcalf, P., , McCullough, S., Yeates, N.J., 1996.
Prevalence of Helicobactor pylori infection in different ethnic groups in New
Zealand children and adults. Aust. N. Z. J. Med. 26: 646-651.
Friedenwald, J., 1912. A clinical study of a thousand cases of ulcer of the stomach
and duodenum. Am J. Med. Sci. 144: 157-170.
Ganza-Gonzalez, A., Anguiano-Igea, S., Otero-Espinar, F.J., Mendez, J.B., 1999.
Chitosan and chondroitin microspheres for oral administration controlled release
of metoclopromide. Eur.J. Pharm. Biopharm. 48: 149–155.
Gaserod, O., Jolliffe, I.G., Hampson, F.C., Dettmar, P.W., Skjak-Brak, G., 1998.The
enhancement of the bioadhesive properties of calcium alginate gel beads by
coating with chitosan. Int. J. Pharm. 175: 237–246.
240
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Gebelein, C.G., Dunn, R.L., 1990.eds. Progress in Biomedical Polymers. : Plenum
Press, New York, pp. 283-284.
Geis, G., Suerbaum, S., Forsthoff, B., Leying, H., Opferkuch, W., 1993.
Ultrastructure and biochemical studies of the flagellar sheath of Helicobactor
pylori. J. Med. Microbiol. 38: 371-377.
Genta, I., Perugini, P., Pavanetto, F., 1998. Different molecular weight chitosan
microspheres: influence on drug loading and drug release. Drug. Dev. Ind.
Pharm. 24: 779–784.
Gerata, R.M., Graham, D.Y., 1996. Helicobactor pylori in gastric pit. N. Engl. J. Med.
335: 250.
Gisbert, J.P., Pajares, R., Pajares, J.M., 2007. Evolution of Helicobactor pylori
therapy from a meta-analytical perspective. Helicobacter. 12: 50–58.
Gitlin, N., McCullough, A.J,, Smith, J.L., Mantell, G., Berman, R., 1987. A
multicenter, double-blind, randomized, placebo-controlled comparison of
nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer
disease. Gastroenterology. 92: 48-53.
Go, M.F., 2002. Review article: natural history and epidemiology of Helicobactor
pylori infection. Aliment. Pharmacol. Ther. 16: 3–15.
Gocho, H., Shimizu, H., Tanioka, A., Chou, T.J. Nakajima, T., 2000. Effect of
polymer chain end on sorption isotherm of water by chitosan. Carbohydr. Polym.
41: 87–90.
Goddard, A., 1998. Review article: Factors influencing antibiotic transfer across the
gastric mucosa. Aliment. Pharmacol. Ther.12:1175–1184.
Goddard, A.F., Spiller, R.C., 1996. The effect of omeprazole on gastric juice
viscosity, pH and bacterial counts. Aliment. Pharm. Ther. 10: 105–109.
Gombotz, W.R., Pettit, D.K., 1995. Biodegradable polymers for protein and peptide
drug delivery. Bioconjug. Chem. 6: 332–351.
Gooday, G.W., Jeuniaux, C., Muzzarelli, R.A.A., 1986. eds. Chitin in Nature and
Technology. Plenum Press, New York, pp. 435.
Graham, D.Y., Adam, E., Reddy, G.T., Agarwal, J.P., Agarwal, R., et al., 1991.
Seroepidemiology of Helicobactor pylori infection in India. Comparison of
developing and developed countries. Dig. Dis. Sci. 36: 1084–1088.
241
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Graham, D.Y., Lew, G.M., Klein, P.D., Evans, D.G., Evans Jr, D.J., Saeed, Z.A., et
al., 1992. Effect of treatment of H pylori infection on the long-term recurrence of
gastric or duodenal ulcer: a randomized, controlled study. Ann. Intern. Med. 116:
705-708.
Graham, D.Y., Malaty, H.M., Evans, D.G, Evans Jr, D.J., Klein, P.D., Adam, E.,
1991. Epidemiology of Helicobactor pylori in an asymptomatic population in the
United States. Gastroenterology. 100:1495-501.
Graham, D.Y, Osato, M.S., Hoffman, J., Opekun, A.R., Anderson, S.Y., El-Zimaity,
H.M., 2000. Furazolidone combination therapies for Helicobactor pylori infection
in the United States. Aliment. Pharmacol. Ther. 14: 211-215.
Graham, D.Y., Rakel, R.E., Fendrick, A.M., Go, M.F., Marshall, B.J., Peura, D.A.,
Scherger, J.E., 1999. Recognizing peptic ulcer disease, keys to clinical and
laboratory diagnosis. Postgrad. Med. 105: 113-133.
Grant, G.T., Morris, E.R., Rees, D.A., Smith, P.J.C., Thom, D., 1973. Biological
interactions between polysaccharides and divalent cations: the egg-box model.
FEBS Lett. 32: 195–198.
Groning, R., Berntgen, M., Georgarakis, M., 1998. Acyclovir serum concentrations
following peroral administration of magnetic depot tablets and the influence of
extracoporal magnets to control gastrointestinal transit. Eur. J. Pharm. Biopharm.
46: 285–291.
Grossman, M.I., Kirsner, J.B., Gillespie, I.E., 1963. Basal and histalog-stimulated
gastric secretion in control subjects and in patients with peptic ulcer or gastric
cancer. Gastroenterology. 45:14-26.
Gupta, P.K., Robinson, J.R., 1992. Oral controlled-release delivery. In: Kydonieus, A.
(Ed.), Treatise on Controlled Drug Delivery. Marcel Dekker, New York, pp. 432
Gupta, V.K., Assmus, M.W., Beckert, T.E., Price, J.C., 2001b. A novel pH- and time-
based multi-unit potential colonic drug delivery system. II Optimization of
multiple response variables. Int. J. Pharm. 213: 93–102.
Gupta, V.K., Beckert, T.E., Price, J.C., 2001a. A novel pH- and time-based multi-unit
potential colonic drug delivery system I Development. Int. J. Pharm. 213: 83–91.
Gustavsson, S., Nyren, O., 1989. Time trends in peptic ulcer surgery, 1956 to 1986: a
nation-wide survey in Sweden. Ann. Surg. 210: 704-709.
242
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Hanawa, T., Ikoma, R., Watanabe, A., Hidaka, M., Sugihara, M., 1996. Preparation
and characterization of sealed heated mixture of ethenzamide and porous calcium
silicate. Chem. Pharm. Bull. 44: 1367–1371.
Hansson, A., Leufven, A., van Ruth, S., 3002. Partition and release of 21 aroma
compounds during storage of a pectin gel system. J. Agric. Food. Chem. 51:
2000–2005.
Harris, A.W., Gummett, P.A., Misiewicz, J.J., Baron, J.H., 1996. Eradication of
Helicobactor pylori in patients with duodenal ulcer lowers basal and peak acid
outputs to gastrin releasing peptide and pentagastrin. Gut, 38: 663-667.
Harris, D., Fell, J., Sharma, H., Taylor, D., 1990a. GI transit of potential bioadhesive
formulations in man: a scintigraphic study. J. Control. Release. 12: 45–53.
Harris, D., Fell, J., Taylor, D., Lynch, J., Sharma, H., 1990b. GI transit of potential
bioadhesive system in rate. J. Control. Release. 12: 55–65.
Hartman, A.W., Nesbitt, R.U., Smith, F.M., Nuessle, N.O., 1975. Viscosities of acacia
and sodium alginate after sterilization by cobalt-60. J. Pharm. Sci. 64: 802–805.
Hartmann, M., Theiss, U., Huber, R., Luhmann, R., Bliesath, H., Wurst, W., et al.,
1996. Twenty four hour intragastric pH profiles and pharmacokinetics following
single and repeated oral administration of the proton pump inhibitor pantoprazole
in comparison to omeprazole. Aliment. Pharmacol.Ther. 10:359-366.
Hazell SL, Lee A, Brady L, Hennessy W., 1989. Campylobacter pyloridis and
gastritis: association with intercellular spaces and adaptation to an environment of
mucus as important factors in the colonization of the gastric epithelium. J. Infect.
Dis. 153: 658–663.
He, P., Davis, S.S., Illum, L., 1998. In vitro evaluation of the mucoadhesive
properties of chitosan microspheres. Int. J. Pharm. 166: 75–88.
He, P., Davis, S.S., Illum, L., 1999. Sustained release chitosan microspheres prepared
by novel spray drying methods. J. Microencapsulation. 16: 343-/355.
Health and Safety Executive, 2002 EH40/2002: Occupational Exposure Limits 2002.
Sudbury: Health and Safety Executive.
Hejazi, R., Amiji, M., 2003. Stomach-specific anti-H. pylori therapy: II. Gastric
residence studies of tetracycline-loaded chitosan microspheres in gerbils. Pharm.
Dev. Technol. 8: 253–262.
243
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Hejazi, R., Amiji, M., 2004. Stomach-specific anti-H. pylori therapy; part III: effect of
chitosan microspheres crosslinking on the gastric residence and local tetracycline
concentrations in fasted gerbils. Int. J. Pharm. 272: 99–108.
Henderson, A.K., Ranger, A.F., Lloyd, J., Mcsharry, C., Mills, R.J., Moran, F., 1984.
Pulmonary hypersensitivity in the alginate industry. Scott. Med. J. 29: 90–95.
Hentschel, E., Brandstatter, G., Dragosics, B., Hirschl, A.M., Nemec, H., Schütze K.,
et al., 1993. Effect of ranitidine and amoxicillin plus metronidazole on the
eradication of Helicobactor pylori and the recurrence of duodenal ulcer. N. Engl.
J. Med. 328: 308-312.
Hernandez-Diaz, S., Rodriguez, L.A., 2000. Association between nonsteroidal anti-
inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an
overview of epidemiologic studies published in the 1990s. Arch. Intern. Med.
160:2093-2099.
Hida, N., Shimoyama Jr ,T., Neville. P., Dixon, M.F., Axon, A.T., et al., 1999.
Increased expression of IL-10 and IL-12 (p40) mRNA in Helicobactor pylori
infected gastric mucosa: relation to bacterial cag status and peptic ulceration. J.
Clin. Pathol. 52: 658–664.
Higuchi, T., 1963. Mechanism of sustained-action medication: theoretical analysis of
rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci. 52: 1145-
1149.
Hilton, A.K., Deasy, P.B., 1992. In vitro and in vivo evaluation of an oral sustained
release floating dosage form of amoxicillin trihydrate. Int. J. Pharm. 86: 79–88.
Hirayama, F., Takagi, S., Kusuhara, H., Iwao, E., Yokoyama, Y., Ikeda, Y., 1996.
Induction of gastric ulcer and intestinal metaplasia in Mongolian gerbils infected
with Helicobactor pylori. J. Gastroenterol. 31: 755–757.
Hoffman, J.S., Cave, D.R., 2001. Treatment of Helicobactor pylori. Curr. Opin.
Gastroenterol. 17: 30-4.
Holt, S., Howden, C.W., 1991. Omeprazole: overview and opinion. Dig. Dis. Sci. 36:
385-93.
Holte, O., Onsoven, E., Myrvold, R., 2003. Sustained release of watersoluble drug
from directly compressed alginate tablets. Eur. J. Pharm. Sci. 20: 403–407.
244
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Hopkins, R.J., Girardi, L.S., Turney, E.A., 1996. Relationship between Helicobactor
pylori eradication and reduced duodenal and gastric ulcer recurrence: a review.
Gastroenterology, 110: 1244-1252.
http://www.cybercolloids.net/library/pectin/properties.php (accessed 26 May 2005)
Cybercolloids Ltd. Introduction to pectins: properties.
Huang, J.Q., Sridhar, S., Hunt, R.H., 2002. Role of Helicobactor pylori infection and
non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.
Lancet. 359: 14-22.
Huang, R.G., Schwartz, J.B., Offner, C.M., 1999. Microencapsulation of
chlorpheniramine maleate-resin particles with crosslinked chitosan for sustained
release. Pharm. Dev. Technol. 4: 107–115.
Huber, R., Hartmann, M., Bliesath, H., Luhmann, R., Steinijans, V.W., et al., 1996.
Pharmacokinetics of pantoprazole in man. Int. J. Clin. Pharmacol. Ther. 34: 185-
194.
Huesca, M., Borgia, S., Hoffman, P., Lingwood, C.A., 1996. Acidic pH changes
receptor binding specificity of Helicobactor pylori: a binary adhesion model in
which surface heat shock (stress) proteins mediate sulfatide recognition in gastric
colonization. Infect. Immun. 64: 2643– 2648.
Hwang, S.J., Park, H., Park, K., 1998. Gastric retentive drug delivery systems. Crit.
Rev. Ther. Drug Carrier Syst. 15: 243–284.
Iannuccelli V, Coppi, G., Bernabei, M.T. Cameroni, R., 1998a. Air compartment
multiple-unit system for prolonged gastric residence. Part I. Formulation study.
Int. J. Pharm. 174: 47–54
Iannuccelli, V., Coppi, G., Leo, E., Fontana, F., Bernabei, M.T., 2000. PVP solid
dispersions for the controlled release of furosemide from a floating multiple-unit
system. Drug Dev. Ind. Pharm. 26: 595–603.
Iannuccelli, V., Coppi, G., Sansone, R., Ferolla, G., 1998b. Air compartment
multiple-unit system for prolonged gastric residence. Part II. In vivo evaluation.
Int. J. Pharm. 174: 55–62.
Ichigawa, M., Watanabe, S., Miyake, Y., 1991. A new multiple-unit oral floating
dosage system. I. Preparation and in vitro evaluation of floating and sustained-
release characteristics. J. Pharm. Sci. 80: 1062–1066.
245
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Ikewaki ,J., Nishizono, A., Goto, T., Fujioka, T., Mifune, K., 2000. Therapeutic oral
vaccination induces mucosal immune response sufficient to eliminate long-term
Helicobactor pylori infection. Microbiol. Immunol. 44: 29-39.
Illum, L., 1998. Chitosan and its use as a pharmaceutical excipient. Pharm. Res. 15:
1326–1331.
Ilver, D., Arnqvist, A., Ogren, J., Frick, I.M., Kersulyte, D., et al., 1998. Helicobactor
pylori adhesin binding fucosylated histo-blood group antigens revealed by
retagging. Science. 279: 373– 377.
Ingani, H.N., Timmermans, J., Mos, A.J., 1987. Conception and in vivo investigation
of peroral sustained release floating dosage forms with enhanced gastrointestinal
transit. Int. J. Pharm. 35: 157–164.
Inoue,Y., Yoshimura, S., Tozuka, Y., Moribe, K., Takuya Kumamoto, T., et al., 2007.
Application of ascorbic acid 2-glucoside as a solubilizing agent for
clarithromycin: Solubilization and nanoparticle formation, Int. J. Pharm. 331: 38–
45.
Inouye, K., Machida, Y., Sannan, T., Nagai, T., 1989. Buoyant sustained release
granules based on chitosan. Drug Des. Dev. 4, 55-/67.
Isenberg, J.I., Selling, J.A., Hogan, D.L., Koss, M.A., 1987. Impaired proximal
duodenal mucosal bicarbonate secretion in patients with duodenal ulcer. N. Engl.
J.Med. 316: 374-379.
Ito, Y., Arai, H., Uchino, K., Iwasaki, K., Shibata, N., Takada, K., 2005. Effect of
adsorbents on the absorption of lansoprazole with surfactant. Int. J. Pharm. 289:
69–77.
Itoh, T., Higuchi, T., Gardener, C., Caldwell, L., 1986. Effect of particle size and food
on gastric residence time of non-disintegrating solids in beagle dogs. J. Pharm.
Pharmacol. 38, 801–806.
Ivy, A.C., 1946. The problem of peptic ulcer. J. Am. Med. Assoc. 132: 1053-1509.
Jain, S.K., Awasthi, A.M., Jain, N.K., Agrawal, G.P., 2005. Calcium silicate based
microspheres of repaglinide for gastroretentive floating drug delivery: preparation
and in vitro characterization. J. Contr. Release. 107: 300–309.
Jarosz, M., Dzieniszewski, J., Dabrowska-Ufniarz, E., Wartanowicz, M., Ziemlanski,
S., et al., 1998. Effects of high dose vitamin C treatment on Helicobactor pylori
246
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
infection and total vitamin C concentration in gastric juice. Eur. J. Cancer. Prev.
7: 449–54.
Jayanthi, G., Jayaswal, S.B., Srivastava, A.K., 1995. Formulation and evaluation of
terfenadine microballoons for oral controlled release. Pharmazie. 50: 769-770
Jin, J., Song, M., Hourston, D.J., 2004. Novel chitosan-based films cross-linked by
genipin with improved physical properties. Biomacromolecules. 5: 162–168.
Johnson, F.A., Craig, D.Q.M., Mercer, A.D., 1997. Characterization of the block
structure and molecular weight of sodium alginates. J. Pharm. Pharmacol. 49:
639–643.
Joseph, N.J., Lakshmi, S., Jayakrishnan, A., 2002. A floating-type oral dosage form
for piroxicam based on hollow polycarbonate microspheres: in vitro and in vivo
evaluation in rabbits. J. Control. Release. 79: 71– 79.
Jungnickd, P.W., 2000. Pantoprazole: A New Proton Pump Inhibitor, Clin. Ther. 22:
1268-1293.
Kalach, N., Mention, K., Guimber, D., Michaud, L., Spyckerelle, C., et al., 2005.
Helicobactor pylori infection is not associated with specific symptoms in
nonulcer-dyspeptic children. Pediatrics. 115: 17—21.
Kas, H.S., 1997. Review: chitosan: properties, preparations and application to
microparticulate systems. J. Microencapsulation. 14: 689-711.
Katayama, H., Nishimura, T., Ochi, S., Tsuruta, Y., Yamazaki, Y., et al., 1999.
Sustained release liquid preparation using sodium alginate for eradication of
Helicobactor pyroli. Biol. Pharm. Bull. 22: 55–60.
Kauffman, G.L., 2000. Duodenal ulcer disease: treatment by surgery, antibiotics, or
both? Adv. Surg. 34: 121-135.
Kawabami, E., Ogata, S.K. , Portorreal, A.C., Magni, A.M., Pardo, M.L., et al., 2001.
Triple therapy with clarithromycin, amoxicillin and omeprazole for Helicobactor
pylori eradication in children and adolescents. Arq. Gastroenterol. 38: 203–206.
Kawahara, T., Teshima, S., Oka, A., Sugiyama, T., Kishi, K., et al., 2001. Type I
Helicobactor pylori lipopolysaccharide stimulates toll-like receptor- 4 and
activates mitogen oxidase 1 in gastric pit cells. Infect. Immun. 69: 4382–4389.
Kawashima, Y., Handa, T., Kasai, A., Takenaka, H., Lin, S.Y., et al., 1985. Novel
method for the preparation of controlled-release theophylline granules coated with
247
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
a polyelectrolyte complex of sodium polyphosphate-chitosan. J. Pharm. Sci. 74:
264-/268.
Kawashima, Y., Niwa, T., Takeuchi, H., Hino, T., Ito, Y., 1991. Preparation of
multiple unit hollow microspheres (microballoons) with acrylic resin containing
tranilast and their drug release characteristics (in vitro) and floating behavior (in
vivo). J. Contr. Release .16: 279–290.
Kawashima, Y., Niwa, T., Takeuchi, H., Hino, T., Ito, Y., 1992. Hollow microspheres
for use as a floating controlled drug delivery system in the stomach. J. Pharm. Sci.
81: 135–140.
Kees, F., Spangler, S., Wellenhofer, M., 1998. Determination of macrolides in
biological matrices by high-performance liquid chromatography with
electrochemical detection. J. Chromatogr. A. 812: 287–293.
Khosla, R., Davis, S.S., 1989. Gastric emptying and small and large bowel transit of
non-disintegrating tablets in fasted subjects. Int. J. Pharm. 52: 1–10.
Khosla, R., Davis, S.S., 1990. The effect of tablet size on the gastric emptying of non-
disintegrating tablets. Int. J. Pharm. 62: R9–R11.
Khosla, R., Feely, L.C., Davis, S.S., 1989. Gastrointestinal transit on non-
disintegrating tablets in fed subjects. Int. J.Pharm. 53: 107–117.
Kikuchi, A., Kawabuchi, M., Sugihara, M., Sakurai, Y., Okano, T., 1997. Pulsed
dextran release from calcium–alginate gel beads. J. Control Release. 47: 21–29.
Kim, C.K., Lee E.J., 1992. The controlled release of blue dextran from alginate beads.
Int. J. Pharm. 79: 11–19.
Kinoshita, M., Baba, K., Nagayasu, A., Yamabe, K., Azuma, M., et al., 2003. Highly
stabilized amorphous 3-bis(4-Methoxyphenyl)methylene-2-indolinone (TAS-301)
in melt-adsorbed products with silicate compounds. Drug Deliv. Ind. Pharm. 29:
523–529.
Klaudianos. S., 1978. Alginate sustained-action tablets. Dtsch. Apoth. Ztg. 118: 683–
684.
Klausner, E.A., Lavy, E., Friedman, M., Hoffman, A., 2003. Expandable
gastroretentive dosage forms. J. Control. Release. 90: 143–162.
248
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Klein, P.D., Gilman, R.H., Leon-Barua, R., Diaz, F., Smith, E.O., et al., 1994. The
epidemiology of Helicobactor pylori in Peruvian children between 6 and 30
months of age. Am. J. Gastroenterol. 89: 2196–2200.
Kofuji, K., Shibata, K., Murata, Y., Miyamoto, E., Kawashima, S., 1999. Preparation
and drug retention of biodegradable chitosan gel beads. Chem. Pharm. Bull. 47:
1494–1496.
Korsmeyer, R.W., Gurny, R., Doelker, E.M., Buri, P., Peppas, N.A., 1983.
Mechanism of solute release from porous hydrophilic polymers. Int. J. Pharm. 15:
25–35.
Kristl, J., Smid-Korbar, J., Struc, E., Schara, M., Rupprecht, H., 1993. Hydrocolloids
and gels of chitosan as drug carriers. Int. J. Pharm. 99: 13–19.
Krogel, I., Bodmeier, R., 1999. Floating or pulsatile drug delivery systems based on
coated effervescent cores. Int. J. Pharm. 187: 175–184.
Kromer. S., Postius, R., Riedal, W.A., Simon WA, Hanauer G, Brand U, et al., 1990.
Pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid
secretion but lacks relevant cytochrome P450 interactions. J. Pharmacol. Exp.
Ther.254: 129-135.
Kubo, W., Konno, Y., Miyazaki, S., Attwood, D., 2004. In situ gelling pectin
formulations for oral sustained delivery of paracetamol. Drug. Dev. Ind. Pharm.
30: 593–599.
Kubo, W., Miyazaki, S., Attwood, D., 2003. Oral sustained delivery of paracetamol
from in-situ gelling gellan and sodium alginate formulations. Int. J. Pharm. 258:
55–64.
Kubo, W., Miyazaki, S., Dairaku, M, Togashi, M., Mikami, R., and Attwood, D.,
2004. Oral sustained delivery of ambroxol from in-situ gelling pectin
formulations. Int. J. Pharm. 271: 233–240.
Kubota, N., Ohga, K., Moriguchi, M., 1991. Permeability properties of glycol
chitosan membrane modified with thiol groups. J. Appl. Polym. Sci. 42: 495–501.
Kumar, M.N.V.R., 2000. A review of chitin and chitosan applications. React. Funct.
Polym. 46: 1–27.
249
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Kurata, J.H., Nogawa, A.N., 1997. Meta-analysis of risk factors for peptic ulcer:
nonsteroidal antiinflammatory drugs, Helicobactor pylori, and smoking. J. Clin.
Gastroenterol. 24: 2-17.
Labenz, J., 2001. Current role of acid suppressants in Helicobactor pylori eradication
therapy. Best Pract. Res. Clin. Gastroenterol. 15: 413–431.
Lai, H.L., Abu-Khalil, A., Craig, D.Q.M., 2003. The preparation and characteristics of
drug-loaded alginate and chitosan sponges. Int. J. Pharm. 251: 175–181.
Laine, L., 2001. Approaches to nonsteroidal anti-inflammatory drug use in the high-
risk patient. Gastroenterology, 120: 594-606.
Laine, L., Hopkins, R.J., Girardi, L.S., 1998. Has the impact of H. pylori therapy on
ulcer recurrence in the United States been overstated: a meta-analysis of
rigorously designed trials. Am. J. Gastroenterol. 93: 1409-1415.
Langer, R.S., Wise, D.L., 1984a. Medical Applications of Controlled Release, vol. I.
CRC Press, Boca Raton, FL., pp. 135-165.
Langer, R.S., Wise, D.L., 1984b. Medical Applications of Controlled Release, vol. II.
CRC Press, Boca Raton, FL., pp. 443-452.
Lanza, F.L., 1998. A guideline for the treatment and prevention of NSAID induced
ulcers. Members of the Ad Hoc Committee on Practice Parameters of the
American College of Gastroenterology. Am. J. Gastroenterol. 93: 2037-2046.
Lee, A., 1994. The microbiology and epidemiology of Helicobactor pylori infection.
Scand. J. Gastroenterol. Suppl. 201: 2-6.
Lee, J.H., Park, T.G., Choi, H.K., 1999. Development of oral drug delivery system
using floating microspheres. J. Microencapsulation 16: 715–729.
Lee, W.J., Wu, M.S., Chen, C.N., Yuan, R.H., Lin, J.T., et al., 1997. Seroprevalence
of Helicobactor pylori in patients with surgical peptic ulcer. Arch. Surg. 132: 430-
434.
Lehmann, K., Dreher, D., 1981. Coating of tablets and small particles with acrylic
resins by fluid bed technology. Int. J. Pharm. Technol. Prod. Manuf. 2: 31–43.
Leodolter, A., Kulig, M., Brasch, H., Meyer-Sabellek, W., Willich, S.N., et al., 2001.
A meta- analysis comparing eradication, healing and relapse rates in patients with
Helicobactor pylori-associated gastric or duodenal ulcer. Alimentary Pharmacol.
Ther. 15: 1949-1958.
250
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Leong, K.W., Mao, H.Q., Truong-Le, V.L., Roy, K., Walsh, S.M., et al., 1998. DNA-
polycation nanospheres as non-viral gene delivery vehicles. J. Control. Release.
53: 183–193.
Leussen HL, Rentel CO, Kotze AF, Lehr,C.M., de Boer, A.J., et al., 1997.
Mucoadhesive polymers in peroral peptide drug delivery, IV: polycarbophil and
chitosan are potent enhancers of peptide transport across intestinal mucosae in
vitro. J.Control. Release, 45: 15–23.
Leussen, H.L., Lehr, C.M., Rentel, C.O, Noach, A.B.J., de Boer, A.G., et al., 1994.
Bioadhesive polymers for the peroral delivery of drugs. J. Control. Release, 29:
329–338.
Levenstein, S., Ackerman, S., Kiecolt-Glaser, J.K., Dubois, A., 1999. Stress and
peptic ulcer disease. J. Am. Med. Assoc. 281: 10-11.
Lewis, R.J., 2004. (ed). Sax’s Dangerous Properties of Industrial Materials, 11th edn.
New York: Wiley, pp.2825–3226.
Li, P., Chang, T.M., Coy, D., Chey, W.Y., 2000. Inhibition of gastric acid secretion in
rat stomach by PACAP is mediated by secretin, somatostatin, and PGE2. Am. J.
Physiol. Gastrointest. Liver Physiol. 278:G121-G127.
Li, Q., Dunn, E.T., Grandmaison, E.W., Goosen, M.F.A., 1992. Application and
properties of chitosan. J. Bioact. Compat. Polym. 7: 370–397.
Li, Q., Liu, N., Shen, B., Zhou, L., Wanga, Y., et al., 2009. Helicobactor pylori
enhances cyclooxygenase 2 expression via p38MAPK/ATF-2 signaling pathway
in MKN45 cells. Cancer Lett. 278: 97–103.
Li, S., Lin, S., Daggy, B.P., Mirchandani, H.L., Chien, Y.W., 2003. Effect of HPMC
and carbopol on the release and floating properties of gastric floating drug
delivery system using factorial design. Int. J. Pharm. 253:13–22.
Lim, J.W., Kim, H., Kim, K.H., 2001, NF-kappaB, inducible nitric oxide synthase and
apoptosis by Helicobactor pylori infection. Free Radic. Biol. Med. 31: 355–366.
Lin, C.K., Hsu, P.I., Lai, K.H., Lo, G.H., Tseng, H.H.,et al., 2002. One-week
quadruple therapy is an effective salvage regimen for Helicobactere pylori
infection in patients after failure of standard triple therapy. J. Clin. Gastroenterol.
34: 547–551.
251
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Lin, S.Y., Lin, P.C., 1992. Effect of acid type, acetic acid and sodium carboxymethyl
cellulose concentration on the formulation, micromeritic, dissolution and floating
properties of theophyllin chitosan microcapsules. Chem. Pharm. Bull. 40: 2491-
2497.
Lin, W.C., Yu, D.G., Yang, M.C., 2005. pH sensitive polyelectrolyte complex gel
microspherescomposed of chitosan/ sodium tripolyphosphate/ dextran
sulfate:swelling kinetics and drug delivery properties. Colloids and Surfaces B:
Biointerfaces. 44: 143–151.
Lin, Y.H., Chang, C.H., Wu, Y.S., Hsu, Y.M., Chiou, S.F., et al., 2009. Development
of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti-
Helicobactor pylori therapy. Biomaterials, 30: 3332–3342.
Lingwood, C., Huesca, M., Kuksis, A., 1992. The glycerolipid receptor for
Helicobactor pylori (and exoenzyme S) is phosphatidylethanolamine. Infect.
Immun. 60: 2470–2474.
Lingwood, C.A., 1993. H. pylori adhesins and receptors, in: Goodwin,S., Worsley,
B.W., (Eds.), Helicobactor pylori: Biology and Clinical Practice, CRC Press, Inc,
Boca Raton, pp. 209– 222.
Liu, L., Fishman, M.L., Kost, J., Hicks, K.B., 2003. Pectin-based systems for colon-
specific drug delivery via oral route. Biomaterials. 24: 3333–3343.
Liu, L., Lu, W., Qian, L., Zhang, X., Zeng, P., Pan, J., 2005. In vitro and in vivo
studies on mucoadhesive microspheres of amoxicillin. J. Control. Release, 102:
135– 144.
Lund, W., 1994. (ed.) The Pharmaceutical Codex: Principles and Practice of
Pharmaceutics, 12th edn. London: Pharmaceutical Press, pp.88.
Malfertheiner, P., Megraud, F., O’Morain, C., Bazzoli, F., El-Omar, E., et al., 2007.
Current concepts in the management of Helicobactor pylori infection: the
Maastricht III Consensus Report. Gut, 56: 772–81.
Manes, G., Balzano, A., Iaquinto, G., Ricci, C., Piccirillo, M.M., et al., 2001.
Accuracy of the stool antigen test in the diagnosis of Helicobactor pylori infection
before treatment and in patients on omeprazole therapy. Aliment. Pharmacol.
Ther. 15: 73-79.
252
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Mansouri, S., Cuie, Y., Winnik, F., Shi, Q., Lavigne, P., et al., 2006. Characterization
of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials. 27:2060–
2065.
Marshall, B., 2002. Helicobactor pylori: 20 years on. Clin. Med. 2: 147– 152.
Marshall, B.J, Warren, J.R., 1984. Unidentified curved bacilli in the stomach of
patients with gastritis and peptic ulceration. Lancet, 1: 1311-1315.
Martindale, 1999. The Complete Drug Reference, 32nd ed. Parfitt, K. (Ed) The
Pharmaceutical Press, UK, pp. 1114, 1377.
Marudova, M., MacDougall, A.J., Ring, S.G., 2004. Pectin–chitosan interactions and
gel formation. Carbohydr. Res. 339: 1933– 1939.
Macek, J., Ptacek, P., Klı́ma , J., 1999. Determination of roxithromycin in human
plasma by high-performance liquid chromatography with spectro photometric
detection. J. Chromatogr. B, Biomed. Sci. Appl. 723: 233–238.
Mc Loughlin, R., Racz, I., Buckley, M., O’connor, H.J., O’morain, C., 2004. Therapy
of Helicobactor pylori. Helicobacter, 9: 42–48.
McArthur, K.E., 1993. Therapy of the uncomplicated ulcer. Semin. Gastrointest. Dis.
4: 27-38.
McConnell, D.B., Baba, G.C., Deveney, C.W., 1989. Changes in surgical treatment of
peptic ulcer disease within a Veterans Hospital in the 1970s and the 1980s. Arch.
Surg. 124: 1164-1167.
Mendeloff, A.I., 1974. What has been happening to duodenal ulcer?
Gastroenterology. 67: 1020-1022.
Menon, A., Ritschel, W.A., Sakr, A., 1994. Development and evaluation of a
monolithic floating dosage form for furosemide. J. Pharm. Sci. 83: 239-245.
Mertz, H.R., Walsh, J.H., 1991. Peptic ulcer pathophysiology. Med. Clin. North Am.
75: 799-814.
Meyer, .F, Wilson, K.T., James, S.P., 2000. Modulation of innate cytokine responses
by products of Helicobactor pylori. Infect. Immun. 68: 6265–6272.
Meyer, J., Dressman, J., Fink, A., Amidon, G., 1985. Effect of size and density on
canine gastric emptying of non-digestible solids. Gastroentrology 89: 805–813.
Meyer, U.A., 1996. Interaction of proton pump inhibitors with cytochromes P450:
Consequences for drug interactions. Yale. J. Biol. Med. 69: 203-209.
253
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Mitchell, H.M., Li, Y.Y., Hu, P.J., Liu, Q., Chen, M., et al., 1992. Epidemiology of
Helicobactor pylori in southern China: identification of early childhood as the
critical period for acquisition. J. Infect. Dis. 166: 149–153.
Miyazaki, S., Nakayama, A., Oda, M., Takada M. Attwoodet, D., 1995. Drug release
from oral mucosal adhesive tablets of chitosan and sodium alginate. Int. J. Pharm.
118: 257–263.
Miyazaki,S., Yamaguchi, H., Yokouchi, C., Takada, M., Hou, W.M., 1988. Sustained
release and intragastric floating granules of indomethacin using chitosan in
rabbits. Chem. Pharm. Bull. 1988; 36: 4033–4038.
Moes, A.J., 1993. Gastroretentive dosage forms. Crit. Rev. Ther. Drug Carrier Syst.
10: 143–195.
Mohammed. F.A., Kheder, H., 2003. Preparation and in vitro/in vivo evaluations of
the buccal bioadhesive properties of slow-release tablets containing miconazole
nitrate. Drug. Dev. Ind. Pharm. 29: 321–337.
Morgan, D.K., Brown, D.M., Rotsch, T.D., and Plasz, A.C., 1991. A reversed-phase
HPLC method for the determination and identification of clarithromycin as the
drug substance and in various dosage forms. J. Pharm. Biomed. Anal, 9: 261-269.
Morris, E.R., Gidley, M.J., Murray, E.J., Powell, D.A., Rees, D.A., 1980.
Characterization of pectin gelation under conditions of low water activity, by
circular dichroism, competitive inhibition and mechanical properties. Int. J. Biol.
Macromol., 2, 327-330.
Morris, J.N., Titmuss, R.M., 1944. Epidemiology of peptic ulcer: vital statistics.
Lancet, 2: 841-845.
Muller, W., Anders, E., 1989. Floating system for oral therapy. WO Patent 89/06956.
Murata, Y., Kofuji, K., Kawashima, S., 2003. Preparation of floating alginate gel
beads for drug delivery to the gastric mucosa. J. Biomater. Sci. Polym. Edn. 14:
581–588.
Murata, Y., Miyashita, M., Kofuji, K., Miyamoto, E., Kawashima, S., 2004. Drug
release properties of a gel bead prepared with pectin and hydrolysate. J. Control.
Release. 95: 61–66.
Murata, Y., Sasaki, N., Miyamoto, E., Kawashima, S., 2000. Use of floating alginate
gel beads for stomach-specific drug delivery. Eur. J. Pharm. Sci. 50: 221–226.
254
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Musabayane, C.T., Munjeri, O., Matavire, T.P., 2003. Transdermal delivery of
chloroquine by amidated pectin hydrogel matrix patch in the rat. Ren. Fail. 25:
525–534.
Muzzarelli, R.A.A, 1973. 2ed. Natural Chelating Polymers. New York: Pergamon
Press, pp. 183–227.
Muzzarelli, R.A.A., 1977. Chitin. London: Pergamon Press, New York. pp. 69.
Myung, K.C., Hongkee, S., Hoo-Kyun, C., 2005. Preparation of mucoadhesive
microspherescontaining antimicrobial agents for eradication of H. pylori. Int.
J.Pharm, 297: 172-179.
Naficy, A.B., Frenck, R.W., Abu-Elyazeed,V., Kim,V., Rao, M.R., et al., 2000.
Seroepidemiology of Helicobactor pylori infection in a population of Egyptian
children. Int. J. Epidemiol. 29: 928–932.
Nagahara, N., Akiyama, Y., Nakao, M., Tada, M., Kitano,V., et al., 1998.
Mucoadhesive microspheres containing amoxicillin for clearance of Helicobactor
pylori. Antimicrob. Agents Chemother. 42: 2492– 2494.
Nagahara, N., Akiyama, Y., Nako, M., Tada, M., Kitano, M., et al., 1998.
Mucoadhesive microspheres containing amoxicillin for clearance of Helicobactor
pylori. Antimicrob. Agent Chemother. 42: 2492–2494.
Nagata, K., Yu, H., Nishikawa, M., Kashiba, M., Nakamura, A., et al., 1998.
Helicobactor pylori generates superoxide radicals and modulates nitric oxide
metabolism. J. Biol. Chem. 273: 14071–14073.
Naisbett, B., Woodley, J., 1995. The potential use of tomato lectin for oral drug
delivery: 3. Bioadhesion in vivo. Int. J. Pharm. 114: 227–236.
Nakatsuka, S., Andrady, L.A., 1992. Permeability of vitamin-B-12 in chitosan
membranes: effect of crosslinking and blending with poly(vinyl alcohol) on
permeability. J. Appl. Polym. Sci. 44: 17–28.
Noach, L.A., Bosma, N.B., Jansen, J., Hoek, F.J., van Deventer, et al., 1994. Mucosal
tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in
patients with Helicobactor pylori infection. Scand. J. Gastroenterol. 29: 425–429.
Nomura, A., Stemmermann, G.N, Chyou, P.H., Perez-Perez, G.I., Blaser, M.J., 1994.
Helicobactor pylori infection and the risk for duodenal and gastric ulceration.
Ann. Intern. Med.120: 977-981.
255
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Noubarani, M., Keyhanfar, F., Motevalian, M., Mahmoudian, M., 2010. Improved
HPLC Method for Determination of Four PPIs, Omeprazole,Pantoprazole,
Lansoprazole and Rabeprazole in Human Plasma. J. Pharm. Pharmaceut. Sci. 13:
1-10, 2010,
Nowicki, M.J., Coyle, W.J., 2001. Severe iron deficiency anemia and asymptomatic
nodular astroduodenitis: an uncommon presentation of Helicobactor pylori
infection in a child. Clin. Pediatr. (Phila.) 40: 111- 114.
Olbe, L., Carlsson, E., Lindberg, P., 2003. A proton-pump inhibitor expedition: the
case histories of omeprazole and esomeprazole. Nat. Rev. Drug. Discov. 2:132-
139.
Oth, M., Franz, M., Timmermans, J., Moes, A., 1992. The bilayer floating capsule: a
stomach-directed drug delivery system for misoprostol. Pharm. Res. 9: 298–302.
Park, H.M., Chrnish, S.M., Rosenek, B., Brunelle, R., Hagrove, B.,et al., 1987.
Hydrogels in Medicine and Pharmacy, vol. III. CRC Press, Boca Raton, FL., pp.
231-235
Park, K., 1988. Enzyme-digestible swelling hydrogels as platforms for long-term oral
drug delivery: synthesis and characterization. Biomaterials. 9: 435.
Parsonnet, J., 1995. The incidence of Helicobactor pylori infection. Aliment.
Pharmacol. Ther. 9: 45-51.
Patel, V.F., Patel, N.M., 2006. Intragastric floating drug delivery system of
cefuroxime cxetil: in vitro Evaluation. AAPS Pharm. Sci. Tech. 7: 17
Patel, V.R., Amiji, M.M., 1998. Preparation and characterisation of peptic ulcer
disease. Current evidence for management freeze-dried chitosan poly (ethylene
oxide) hydrogels for site strategies, Can. Fam. Physician 44: 1481–1488.
Paul, W., Sharma, C.P., 2000. Chitosan, a drug carrier for the 21st century: a review.
S.T.P. Pharma. Sci. 10: 5–22.
Pav, B., Misztal, G., Hopkala, H., Drozd, J., 2002 Development and validation of a
HPLC method for the determination of cetrizine in pharmaceutical dosage forms.
Pharmazie, 57: 313-315.
Pavics, L., 1970. Comparison of rheological properties of mucilages. Acta. Pharm.
Hung. 40: 52–59.
256
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Peek Jr, R.M., Blaser, M.J., 1997. Pathophysiology of Helicobactor pylori-induced
gastritis and peptic ulcer disease. Am. J. Med.102: 200-207.
Peppas, N.A., 1985. Analysis of Fickian and non-Fickian drug release from polymers.
Pharm. Acta Helv. 60, 110–111.
Peppas, N.A., Little, M.D., Huang, Y., 2000. Bioadhesive controlled release systems.
In:Wise, D.L. (Ed.), Handbook of Pharmaceutical Controlled Release Technology.
Marcel Dekker, New York, pp. 255–269.
Peppas, N.A., Ponchel, G., Duchene, D., 1987, Bioadhesive analysis of controlled
release systems, Part 2. Time dependent bioadhesive stress of poly (acrylic acid)
containing systems. J. Controlled Release. 5: 143–149.
Peppas, N.A., Sahlin, J.J., 1989. A simple equation for the description of solute
release. III. Coupling of diffusion and relaxation, Int. J. Pharm. 57: 169–172.
Peterson, W.L., 1991. Helicobactor pylori and peptic ulcer disease. N. Engl. J. Med.
324: 1043–1048.
Peterson, W.L., Ciociola, A.A., Sykes, D.L., McSorley, D.J., Webb, D.D., 1996.
Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal
ulcers, eradicating H. pylori and reducing ulcer recurrence. Aliment.
Pharmacol.Ther. 10: 251–261.
Peterson,W.L., Graham ,D.Y., 2002. Helicobactor pylori. In Feldman, M., editor.
Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 7th ed. Elsevier,
Philadelphia, PA., pp. 732-46.
Pillay, V., Danckwerts, M.P., Fassihi. R., 2002. A crosslinked calciumalginate–
pectinate–cellulose acetophthalate gelisphere system for linear drug release. Drug
Delivery. 9: 77–86.
Porter, S.C., Ghebre-Sellassie, I., 1994, Key factors in the development of modified-
release pellets. In: Ghebre-Sellassie, I. (Ed.), Multiparticulate oral drug delivery,
Marcel Dekker, New York, pp. 217–284.
Poynard, T., Lemaire, M., Agostini, H., 1995. Meta-analysis of randomized clinical
trials comparing lansoprazole with rantidine or famotidine in the treatment of
acute duodenal ulcers. Eur. J. Gastroenterol. Hepatol. 7: 661-665.
257
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Pue, M.A., Laroche, J., Meineke, I., de Mey, C., 1993. Pharmacokinetics of
pantoprazole following single intravenous and oral administration to healthy male
subjects. Eur. J. Clin. Phannacol.44:575-578.
Rachmilewitz, D., Karmeli, F., Eliakim, R., Stalnikowicz, R., Ackerman, Z., Amir,
G., et al., 1994. Enhanced gastric nitric oxide synthase activity in duodenal ulcer
patients. Gut. 35: 1394– 1397.
Raffin, R.P., Colome, L.M., Pohlmann, A.R., Guterres, S.S., 2006. Preparation,
characterization, and in vivo anti-ulcer evaluation of pantoprazole-loaded
microparticles. Eur. J. Pharm. 63: 198–204.
Rahman, M.M., Mahalanabis, D., Sarker, S.A., Bardhan, P.K., Alvarez, J.O., et al.,
1998. Helicobactor pylori colonization in infants and young children is not
necessarily associated with diarrhea. J. Trop. Pediatr. 44: 283–287.
Rajaonarivony, M., Vauthier, C., Couarraze, G., Puisieux, F., Couvreur, P., 1993.
Development of a new drug carrier made from alginate. J. Pharm. Sci. 82: 912–
917.
Rajinikanth, P.S., Balasubramanium, J., Mishra, B., 2007. Development and
evaluation a novel floating in situ gelling system of amoxicillin for eradicating of
Helicobactor pylori, Int.J.Pharm. 335: 114-122.
Rao, M.Y., Suresh, B., 2011. In Gastroretentive drug delivery systems, (Eds) Rao,
M.Y., Jithin, A.V., Advances in drug delivery - I, PharmaMed Press, Hyderabad.
pp. 77-138
Reiley, C.M., Fell, F., 1996 Development and validation of analytical methods.
Prog.Pharm. Biomed. Anal. 3, 20-22
Remunan-Lopez, C., Portero, A., Vila-Jato, J.L., Alonso, M.J., 1998. Design and
evaluation of chitosan/ethylcellulose mucoadhesive bilayered devices for buccal
drug delivery. J. Control. Release, 55: 143– 152.
Rieder, G., Hofmann, J.A., Hatz, R.A., Stolte, M., Enders, G.A., 2003. Up-regulation
of inducible nitric oxide synthase in Helicobactor pylori-associated gastritis may
represent an increased risk factor to develop gastric carcinoma of the intestinal
type. Int. J. Med. Microbiol. 293: 403–412.
Ritchie Jr, W.P.., 1975. Acute gastric mucosal damage induced by bile salts, acid, and
ischemia. Gastroenterology, 68: 699-707.
258
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Robinson, J.R., Lee, V.H.L., 1987. Controlled Drug Delivery: Fundamentals and
Applications, 2nd ed. Marcel Dekker, New York, pp 5-45
Rotsch, T.D., Spanton, M., Cugier, P., and Plasz, A.C., 1991. Determination of
clarithromycin as a conta-minant on surfaces by HPLC using electronical
detection. Pharm. Res., 8: 989-991.
Rouge, N., Buri, P., Doelker, E., 1996. Drug absorption sites in the gastrointestinal
tract and dosage forms for site-specific delivery. Int. J. Pharm. 136: 117–139.
Rouge, N., Cole, E.T., Doelker, E., Buri, P., 1998. Buoyancy and drug release
patterns of floating minitablets containing piretanide and atenolol as model drugs.
Pharm. Dev. Technol. 3:73–84.
Sabnis, S., Rege, P., Block, L.H., 1997. Use of chitosan in compressed tablets of
diclofenac sodium: inhibition of drug release in an acidic environment. Pharm.
Dev. Technol. 2: 243–255.
Sakr, A.M., Elsabbagh, H.M., Shalaby, A.H., 1978. Effect of the technique of
incorporating sodium alginate on its binding and/or disintegrating effectiveness in
sulfathiazole tablets. Pharm. Ind. 40: 1080–1086.
Sakurai, K., Maegawa, T., Takahashi, T., 2000. Glass transition temperature of
chitosan and miscibility of chitosan/poly (N-vinyl pyrrolidone) blends. Polymer.
41: 7051–7056.
Santus, G., Lazzarini, G., Bottoni, G., Sandefer, E.P., Page, R.C., et al., 1997. An in
vitro in vivo investigation of oral bioadhesive controlled release furosemide
formulations. Eur. J. Pharm. Biopharm. 44: 39-52.
Sato, Y., Kawashima, Y., Takeuchi, H., Yamamoto, H., 2004. In vitro and in vivo
evaluation of riboflavin-containing microballoons for a floating controlled drug
delivery system in healthy humans. Int. J. Pharm.275: 97–107.
Sato,Y., Kawashima,Y., Takeuchi, H.,Yamamoto, H., 2004b. In vitro evaluation of
floating and drug releasing behaviors of hollow microspheres (microballoons)
prepared by the emulsion solvent diffusion method. Eur. J. Pharm. Biopharm. 57:
235–243.
Sawayangi Y, Nambu N, Nagai T., 1982. Use of chitosan for sustained release
preparations of water soluble drugs. Chem. Pharm. Bull. 30: 4213–4215.
259
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Sawayangi, Y., Nambu, N., Nagai, T., 1982. Enhancement of dissolution properties of
griseofulvin from ground mixtures with chitin or chitosan. Chem. Pharm. Bull. 30:
4464–4467.
Schliecker, G., Schmidt, Thanoo, B.C., Sunny, M.C., Jayakrishnan, A., 1993. Oral
sustained-release drug delivery systems using polycarbonate microspheres capable
of floating on the gastric fluid. J. Pharm. Pharmacol. 45: 21–24.
Schwartz, H.R., Krause, B., Sahba, M., Haber, A., Weissfeld, P., et al., 1998.
Tripleversus dual therapy for eradicating Helicobactor pylori and preventing ulcer
recurrence: a randomized, double blind, multicenter study of lansoprazole,
clarithromycin, and/or amoxicillin in different dosing regimens,
Am.J.Gastroenterol. 93: 584–590.
Senel, S., Ikinci, G., Kas, S., Yousefi-Rad,A., Sargon, M.F., Hincal, A.A., 2000.
Chitosan films and hydrogels of chlorhexidine gluconate for oral mucosal
delivery. Int. J. Pharm. 193: 197–203.
Sezer, A.D., Akbuga, J., 1999. Release characteristics of chitosan-treated alginate
beads, 1: sustained release of a macromolecular drug from chitosan treated
alginate beads. J. Microencapsul. 16: 195–203.
Sharma, S. P., 2008. H pylori and gastric cancer in Asia: enigma, or a play on words?
Lancet Oncol. 9: 827.
Sharma, S., Pawar, A., 2006. Low density multiparticulate system for pulsatile release
of meloxicam. Int. J. Pharm. 313: 150–158.
Sher,P., Ingavle,G., Ponrathnam, S., Pawar, A.P., 2007, Low density porous carrier:
Drug adsorption and release study by response surface methodology using
different solvents Int. J. Pharm. 331: 72-83.
Sheth, P.R., Tossounian, J., 1984. The hydrodynamically balanced system (HBS™):
A novel drug delivery system for oral use. Drug Dev. Ind. Pharm. 10: 313–339.
Shin, J.M., Besancon, M., Prinz, C., Simon, A., Sachs, G., 1994. Continuing
development of acid pump inhibitors: site of action of pantoprazole. Aliment.
Pharmacol. Ther. 8:11–23.
Shirashi, S., Arahira, M., Imai, T., Otagiri, M., 1990. Enhancement of dissolution
rates of several drugs by low molecular weight chitosan and alginate. Chem.
Pharm. Bull. 38: 185–187.
260
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Shiraishi, S., Imai, T., Otagiri, M., 1993. Controlled release of indomethacin by
chitosan-polyelectrolyte complex: optimizationand in vivo/in vitro evaluation. J.
Control. Release. 25: 217-/225.
Shu, X.Z., Zhu, K.J., 2000. A novel approach to prepare tripolyphosphate/ chitosan
complex beads for controlled release drug delivery. Int. J. Pharm. 201: 51-58.
Sidebotham, R.L., Batten, J.J., Karim, Q.N., Spencer, J., Baron, J.H., 1991.
Breakdown of gastric mucus in presence of Helicobactor pylori. J. Clin. Pathol.
44: 52–57.
Singh, B.N., Kim, K.H., 2000. Floating drug delivery system: an approach to oral
controlled drug delivery via gastric retention. J. Control. Rel. 63: 235–259.
Singha, M, Prasada, K.N., Surender K. Yachha, K.S, Saxenaa, A., et al., 2006.
Helicobactor pylori infection in children: prevalence, diagnosis and treatment
outcome. Trans. R. Soc. Trop. Med. Hyg. 100: 227—233.
Singla AK, Chawla M., 2001. Chitosan: some pharmaceutical and biological aspects –
an update. J. Pharm. Pharmacol. 53: 1047–1067.
Sirois, P., Amidon, G., Meyer, J., Doty, J., Dressman, J., 1990. Gastric emptying of
nondigestible solids in dogs: a hydrodynamic correlation. Am. J. Physiol. 258:
G65–G72.
Skouloubris, S., De Reuse, H., Labigne, A., 2000. Bacteriology and pathogenicity of
Helicobactor pylori. Rev. Prat. 50: 1409–1413.
Sohn Y.T., Rhee, Im, W.B., 2000. Polymorphism of clarithromycin. Arch. Pharm.
Res. 23: 381-384.
Sonnenberg ,A., 1995. Temporal trends and geographical variations of peptic ulcer
disease. Aliment. Pharmacol. Ther. 9: 3-12.
Soppimath, K.S., Kulkarni, A.R., Aminabhavi, T.M., 2001. Development of hollow
microspheres as floating controlled release systems for cardiovascular drugs:
preparation and release characteristics. Drug Dev. Ind. Pharm. 27: 507-515.
Spechler, J.S., 2002. Peptic ulcer disease and its complications. In: Feldman, M.,
editor. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 7th ed.
Elsevier, Philadelphia, pp.747-781.
261
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Sriamornsak, P., Nunthanid, J., Wanchana, S., Luangtana-Anan, M., 2003. Composite
film-coated tablets intended for colon-specific delivery of 5-aminosalicylic acid:
using de-esterified pectin. Pharm. Dev. Technol.8: 311–318.
Sriamornsak, P., Thirawong, N., Puttipipatkhachorn, S., 2005. Emulsion gel beads of
calcium pectinate capable of floating on the gastric fluid: effect of some additives,
hardening agent or coating on release behaviour of metronidazole. Eur. J. Pharm.
Sci. 24: 363–373.
Stabile, B.E., Passaro Jr, E., 1984. Duodenal ulcer, a disease in evolution. Curr.
Probl. Surg. 21: 1-79.
Stanciu, C., Bennett, J.R., 1974. Alginate/antacid in the reduction of
gastrooesophageal reflux. Lancet, 1: 109–111.
Stithit, S., Chen, W., Price, J.C., 1998. Development and characterization of buoyant
theophylline microspheres with near zero order release kinetics. J.
Microencapsulation.15: 725-737.
Stockwell, A.F., Davis, S.S., Walker, S.E., 1986. In vitro evaluation of alginate gel
systems as sustained release drug delivery systems. J. Controlled Release. 3: 167–
175.
Streubel, A., Siepmann, J., Bodmeier, R., 2002. Floating microparticles based on low
density foam powder. Int. J. Pharm. 241: 279–292.
Streubel, A., Siepmann, J., Bodmeier, R., 2003a. Floating matrix tablets based on low
density foam powder: effects of formulation and processing parameters on drug
release. Eur. J. Pharm. Sci. 18: 37–45.
Streubel, A., Siepmann, J., Bodmeier, R., 2003b. Multiple unit gastroretentive drug
delivery systems: a new preparation method for low density microparticles. J.
Microencapsul. 20: 329–347.
Sturdevant, R.A.L., 1976. Epidemiology of peptic ulcer. Am. J. Epidemiol. 104: 9-14.
Suerbaum, S., Michetti, P., 2002. Helicobactor pylori infection. N. Engl. J. Med. 347:
1175– 1186.
Sun, Y.Q, Girgensone, I., Leanderson, P., Petersson, F., Borch K., 2005. Effects of
antioxidant vitamin supplements on Helicobacter pylori-induced gastritis in
Mongolian gerbils. Helicobacter. 10 : 33-42
262
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Sungthongjeen, S., Paeratakul, O., Limmatvapirat, S., Puttipipatkhachor- n, S., 2006.
Preparation and in vitro evaluation of a multiple-unit floating drug delivery
system based on gas formation technique. Int. J. Pharm. 324:136–143.
Sungthongjeen, S., Sriamornsak, P., Pitaksuteepong, T., Somsiri, A.,
Puttipipatkhachorn, S., 2004. Effect of degree of esterification of pectin and
calcium amount on drug release from pectin-based matrix tablets. A.A.P.S. Pharm.
Sci. Tech. 5: E9.
Susser, M., Stein, Z., 1962. Civilization and peptic ulcer. Lancet, 1: 115-119.
Svanes, C., Soreide, J.A., Skarstein, A., Fevang, B.T., Bakke, P., Vollset, S.E., et
al.1997. Smoking and ulcer perforation. Gut. 41: 177-180.
Sweetman, S.C., 2005 (ed.) Martindale: the Complete Drug Reference, 34th edn.
London: Pharmaceutical Press, pp.1580.
Takeuchi, H., Yamamoto, H., Niwa, T., Hino T, Kawashima Y., 1996. Enteral
absorption of insulin in rats from mucoadhesive chitosan-coated liposomes.
Pharm. Res. 13: 896–901.
Talukder, R., Fassihi, R., 2004a. Gastroretentive delivery systems: a mini review.
Drug. Dev. Ind. Pharm. 30: 1019–1028.
Talukder, R., Fassihi, R., 2004b. Gastroretentive delivery systems: hollow beads.
Drug Dev. Ind. Pharm. 30: 405–412.
Tanaka M, Ohkubo T, Otani K, , Suzuki, A., Kaneko, S., et al., 1997. Metabolic
disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin
4’-hydroxylation phenotype and genotype. Clin. Pharmacol. Thert. 62:619-628.
Tanaka M, Yamazaki H, Ryokawa Y, , Hakusui, H., Nakamichi, N., et al., 1996.
Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor, after
single and multiple oral doses in healthy Japanese volunteers. Int. J. Clin.
Pharmaco.lTher.34:415-419.
Tang Y, Subbu S. Venkatraman, S.S., Boey, F.Y.C., Wang, L., 2007 Sustained release
of hydrophobic and hydrophilic drugs from a floating dosage form. Int. J. Pharm.
336: 159–165.
Taninaka, C., Ohtani, H., Hanada, E., Kotaki, H., Sato,H., Iga,T., 2000. Determination
of erythromycin, clarithromycin, roxithromycin, and azithromycin in plasma by
263
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
high-performance liquid chromatography with amperometric detection. J.
Chromatogr. B, Biomed. Sci. Appl.738: 405-411.
Tasker, R.A., Ross, S.J., Dohoo, S.E., Elson, C.M., 1997. Pharmacokinetics of an
injectable sustained-release formulation of morphine for use in dogs. J. Vet.
Pharmacol. Ther. 20: 362–367.
Thanoo, B.C., Sunny, M.C., Jayakrishnan, A., 1992. Crosslinked chitosan
microspheres: preparation and evaluation as a matrix for the controlled release of
pharmaceuticals. J. Pharm. Pharmacol. 44: 283-286.
Thanoo, B.C., Sunny, M.C., Jayakrishnan, A., 1993. Oral sustained-release drug
delivery systems using polycarbonate microspheres capable of floating on the
gastric fluid. J.Pharm. Pharmacol. 45: 21–24.
Thanou, M., Verhoef, J.C., Junginger, H.E., 2001. Chitosan and its derivatives as
intestinal absorption enhancers. Adv. Drug. Deliv. Rev. 50: S91–101.
Tho, I., Sande, S.A., Kleinebudde, P., 2003. Disintegrating pellets from a water-
insoluble pectin derivative produced by extrusion/spheronisation. Eur. J. Pharm.
Biopharm. 56: 371–380.
Thomas, J.E., Dale, A., Harding, V., Coward, W.A., Cole, T.J., Weaver, L.T., 1999.
Helicobactor pylori colonization in early life. Pediatr. Res. 45: 218–223.
Thomas, S., 1990. Wound Management and Dressings. London: Pharmaceutical
Press, pp.43–49.
Thomas, S., 2000. Alginate dressings in surgery and wound management—Part 1. J.
Wound Care, 9: 56–60.
Tonnesen, H.H., Karlsen, J., 2002. Alginate in drug delivery systems. Drug. Dev.
Ind. Pharm. 28: 621–630.
Torano, J.S., Guchelaar,H.J., 1998. Quantitative determination of the macrolide
antibiotics erythromycin, roxithromycin, azithromycin and clarithromycin in
human serum by high-performance liquid chromatography using pre-column
derivatization with 9-fluorenylmethyloxycarbonyl chloride and fluorescence
detection. J. Chromatogr. B, Biomed. Sci. Appl. 720: 89–97
Torres, J., Perez-Perez, G., Goodman, K.J., Atherton, J.C. Gold, B.D., et al., 2000. A
comprehensive review of the natural history of Helicobactor pylori infection in
children. Arch. Med. Res. 31: 431–469.
264
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Tozaki, H., Fujita, T., Odoriba, T., Terabe, A., Okabe, S., et al., 1999. Validation of a
pharmacokinetic model of colon-specific drug delivery and the therapeutic effects
of chitosan capsules containing 5-aminosalicylic acid on 2,4,6-trinitrobenzene
sulphonic acid-induced ulcerative colitis in rats. J.Pharm. Pharmacol. 51: 1107–
1112.
Tozaki, H., Fujita, T., Odoriba, T., Terabe, A., Suzuki, T., et al., 1999. Colon specific
delivery of R 68070, a new thromboxane synthase inhibitor using
chitosancapsules: therapeutic effects against 2,4,6-trinitrobenzene sulphonic acid-
induced ulcerative colitis in rats. Life. Sci.64: 1155–1162.
Trebesius, K., Panthel, K., Strobel, S., Vogt, K., Faller, G., et al., 2000. Rapid and
specific detection of Helicobactor pylori macrolide resistance in gastric tissue by
fluorescent in situ hybridization. Gut, 46: 608-14.
Treiber, G., Lambert, J.R., 1998. The impact of Helicobactor pylori eradication on
peptic ulcer healing. Am. J. Gastroenterol. 93: 1080-1084.
Tunis, S.R., Sheinhait, I.A., Schmid, C.H., Bishop, D.J., Ross, S.D., 1997.
Lansoprazole compared with histamine2-receptor antagonists in healing gastric
ulcers: a meta-analysis. Clin. Ther. 19: 743-757.
U. S. Pharmacopeia National Formulary, USP 26-NF 21, 2003. 3th Ed.,Mack Printing
Company: Easton, U.S.A., pp. 2439-2445.
Uemura, N., Okamoto, S., Yamamoto, S., 2002. H. pylori infection and the
development of gastric cancer. Keio. J. Med. 51: 63-68.
Umamaheshwari, R.B, Jain, P., Jain, N.K., 2003a. Site specific drug delivery of
acetohydroxamic acid for treatment of H. pylori. S.T.P. Pharma. Sci. 13: 41– 48.
Umamaheshwari, R.B., Jain S., Tripathi, P.K., Agrawal, G.P., Jain, N.K., 2002.
Floating-bioadhesive microspheres containing acetohydroxamic acid for clearance
of Helicobactor pylori. Drug Deliv. 9: 223– 231.(154)
Umamaheshwari, R.B., Jain, N.K., 2004. Receptor-mediated targeting of lipobeads
bearing acetohydroxamic acid for eradication of Helicobactor pylori. J. Control.
Release, 99: 27–40.
Umamaheshwari, R.B., Jain, S., Bhadra, D., Jain, N.K., 2003b. Floating microspheres
bearing acetohydroxamic acid for the treatment of Helicobactor pylori. J. Pharm.
Pharmacol. 55: 1607– 1613.
265
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Umamaheshwari, R.B., Jain, S., Jain, N.K., 2003c. A new approach in gastroretentive
drug delivery system using cholestyramine. Drug Deliv. 10: 151– 160.
Unge, P., Andersson T., 1997. Drug interactions with proton pump inhibitors. Drug
Saf.16:171-179.
Urquhart, J., Theeuwes, F., 1984. Drug delivery system comprising a reservoir
containing a plurality of tiny pills. US Patent 4,434,153.
Vakil,N., 2005. Helicobactor pylori: Factors Affecting Eradication and Recurrence.
Am. J. Gastroenterol. 100: 2393–2394
Vandenbossche, G.M.R., Remon, J.P., 1993.Influence of the sterilization process on
alginate dispersions. J. Pharm. Pharmacol. 45:484–486.
Van-der Hulst, R.W.M., Rauws, E.A.J., Koycu, B, Keller, J.J., Bruno, M.J., et al.,
1997. Prevention of ulcer recurrence after eradication of Helicobactor pylori: a
prospective long-term follow-up study. Gastroenterology. 113: 1082-1086.
Vennat. B., Lardy, F., Arvouet-Grand, A., Pourrat, A., 1998. Comparative
texturometric analysis of hydrogels based on cellulose derivatives, carraghenates,
and alginates: evaluation of adhesiveness. Drug. Dev. Ind. Pharm. 24: 27–35.
Vervaet, C., Baert, L., Remon, J.P., 1995. Extrusion–spheronization: a literature
review. Int. J. Pharm. 116: 131–146.
Veski, P., Marvola, M., 1993. Sodium alginates as diluents in hard gelatin capsules
containing ibuprofen as a model drug. Pharmazie. 48: 757–760.
Veski, P., Marvola, M., Smal, J., Heiskanen, I., Jurjenson, H., 1994.
Biopharmaceutical evaluation of pseudoephedrine hydrochloride capsules
containing different grades of sodium alginate. Int. J. Pharm. 111: 171–179.
Vogt, T.M., Johnson, R.E., 1980. Recent changes in the incidence of duodenal and
gastric ulcer. Am. J. Epidemiol. 111: 713-720.
Walan, A., Bader, J.P., Classen, M., Lamers, C.B., Piper, D.W., et al., 1989. Effect of
omeprazole and ranitidine on ulcer healing and relapse rates in patients with
benign gastric ulcer. N. Engl. J. Med. 320: 69-75.
Walkenstrom, P., Kidman, S., Hermansson, A. M., Rasmussen, P. B., Hoegh, L.,
2003. Microstructure and rheological behaviour of alginate/pectin mixed gels.
Food Hydrocolloids, 17: 593–603.
266
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Walsh, J.H., Peterson, W.L., 1995. The treatment of Helicobactor pylori infection in
the management of peptic ulcer disease. N. Engl. J.Med. 333: 984-991.
Wang, G., Liao,W., 2002. Automatic identification of different types of defects in
radiographic images. NDT&E Int. 35: 519–528.
Wang, K., He, Z., 2002. Alginate-konjac glucomannan-chitosan beads as controlled
release matrix. Int. J. Pharm. 244: 117–126.
Warren, J.R., Marshall, B.J., 1983. Unidentified curved bacilli on gastric epithelium
in active chronic gastritis. Lancet, 1: 1273–1275.
Wellman, H., 1984. Gastric emptying of enteric-coated tablets. Dig. Dis. Sci. 29: 207–
212.
Whitehead, L., Fell, J.T., Collett, J.H., Sharma, H.L., Smith, A.M., 1998. Floating
dosage forms: an in vivo study demonstrating prolonged gastric retention. J.
Contr. Release. 55: 3–12.
Wolfe, M.M., Lichtenstein, D.R., Singh, G., 1999. Gastrointestinal toxicity of
nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. 340:1888-1899.
Wolfe, M.M., Sachs, G., 2000. Acid suppression: optimizing therapy for
gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress related
erosive syndrome. Gastroenterology 118: S9-S31.
Wylie, C.M., 1981. The complex wane of peptic ulcer: trends in duodenal ulcer
admission to 790 hospitals, 1974-1979. J. Clin. Gastroenterol. 3: 333-339.
Xiaoqiang X, Minjie, S., Feng, Z., Yiqiao, H., 2006. Floating matrix dosage form for
phenoporlamine hydrochloride based on gas forming agent: In vitro and in vivo
evaluation in healthy volunteers. Int. J. Pharm. 310: 139–145
Yamac, D., Ayyildiz, T., Coskun, U., Akyurek, N., Dursun, A., et al., 2008.
Cyclooxygenase-2 expression and its association with angiogenesis, Helicobactor
pylori, and clinicopathologic characteristics of gastric carcinoma. Pathol. Res.
Pract. 204: 527–536.
Yang, L., Eshraghi, J., Fassihi, R., 1999. A new intragastric delivery system for the
treatment of Helicobactor pylori associated gastric ulcer: in vitro evaluation. J.
Control. Release, 57: 215– 222.
267
BIBLIOGRAPHY
BIBLIOG
RAPHY BIB
Yeomans, N.D., Tulassay, Z., Juhasz, L., Racz, I., Howard, J.M., et al., 1998. A
comparison of omeprazole with rantidine for ulcers associated with nonsteroidal
anti-inflammatory drugs: the astronaut study group. N. Engl. J. Med. 338: 719-26.
Yomota, C., Miyazaki, T., Okada S., 1994. Sustained-release effect of the direct
compressed tablet based on chitosan and Na alginate. Yakugaku Zasshi, 114: 257–
263.
Yuasa, H., Akutagawa, M., Hashizume, T., Kanaya, Y., 1996b. Studies on internal
structure of tablets. VI. Stress dispersion in tablets by excipients. Chem. Pharm.
Bull. 44: 378–382.
Yuasa, H., Asahi, D., Takashima, Y., Kanaya, Y., Shinozawa, K., 1994. Application
of calcium silicate for medicinal preparation. I. Solid preparation adsorbing an
oily medicine to calcium silicate. Chem. Pharm. Bull. 42: 2327–2331.
Yuasa, H., Takashima, Y., Kanaya, Y., 1996a. Studies on the development of
intragastric floating and sustained release preparation. I. Application of calcium
silicate as a floating carrier. Chem. Pharm. Bull. 44: 1361– 1366.
Zatz, J.L., Woodford, D.W., 1987. Prolonged release of theophylline from aqueous
suspensions. Drug. Dev. Ind. Pharm. 13: 2159–2178.
Zeng, N., Athmann, C., Kang, T., Lyu, R.M., Walsh, J.H., et al., 1999. PACAP type I
receptor activation regulates ECL cells and gastric acid secretion. J. Clin. Invest.
104: 1383-91.
Zikakis JP, 1974. (ed). Chitin, Chitosan and Related Enzymes. New York: Academic
Press, pp.119-133
Zojaji, H., Talaie, R., Mirsattari, D., Haghazali, M., Molaei, M., et al., 2009.The
efficacy of Helicobactor pylori eradication regimen with and without vitamin C
supplementation. Dig. Liver Dis. 41: 644-647.